Year: 2022

Conference Call to be Held at 8:00 am ET Today SAN CLEMENTE, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) — ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial and operating results for the third quarter ended September 30, 2022 and provided a corporate strategic update. Third Quarter and Subsequent HighlightsIn August, Paul F. Hickey, a seasoned executive with over 25 years of medical device commercialization experience, was appointed President and Chief Executive Officer. In August, received U.S. Food and Drug Administration (FDA) 510(k) clearance for the disposable Gastro Intestinal Balloon Indicator (GIBI HD™) calibration tube for use in gastric and bariatric procedures. In August, appointed seasoned sales and marketing executive,...

Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome (FXS); topline results expected second-half 2023 $55.9 million in cash and cash equivalents at September 30, 2022; Cash runway into first quarter 2024 DEVON, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today reported financial results for the third quarter ended September 30, 2022, and provided an overview of recent operational highlights and a pipeline update. “Enrollment in our confirmatory pivotal Phase 3 RECONNECT trial continues, and we expect topline results in the second half of 2023,” said Armando Anido, Chairman and Chief Executive Officer...

Year-over-Year Revenue Growth of 34.9% to $72.8 million Strong Retail Performance and Patient Expansion in Virginia with 48.4% Sequential Increase in Retail Sales in the Commonwealth BOCA RATON, Fla., Nov. 14, 2022 (GLOBE NEWSWIRE) — Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF), a vertically integrated, multi-state cannabis operator, announced certain preliminary financial results for the quarter ended September 30, 2022 (“Q3 2022”). The Company also announced that it is in the process of completing its interim asset impairment assessment and expects to record a non-cash, indefinite-lived asset impairment charge in the range of $35.0 to $49.0 million (after-tax of $24.8 to $34.7 million). All financial information is provided in U.S. dollars unless otherwise indicated and is prepared under U.S. Generally...

TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) — NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, November 14, 2022 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce the filing of its interim financial statements for the three-month period ending September 30, 2022 (“Q3 2022”). Management commentary During the third quarter we successfully completed a complex technical and regulatory transfer of a sizable portion of our Canadian products, which we deemed necessary...

Consolidated Net Product Revenue of $13.6 Million, up 11% vs. Third Quarter of 2021Net Product Revenue Was Unfavorably Impacted by Approximately $800,000 in Foreign Currency FluctuationsExcluding Fluctuations in Foreign Currency Exchange Rates, Consolidated Net Product Revenue Would Have Been $14.4 Million, up 18% vs. Third Quarter of 2021 Record Third Quarter U.S. Revenue and End User Demand up 27% vs. Third Quarter of 2021 Record International End User Demand up 27% vs. Third Quarter of 2021 Company Entered into Agreement for Radiation Retinopathy Trial with the DRCR Retina NetworkATLANTA, Nov. 14, 2022 (GLOBE NEWSWIRE) — Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining...

Demonstrates Strong Execution Despite Challenging Macroeconomic Environment and Unfavorable e-Commerce Environment Raises Full Year 2022 Revenue Guidance Range of $91 million to $100 million REDMOND, Wash., Nov. 14, 2022 (GLOBE NEWSWIRE) — Hour Loop, Inc. (NASDAQ: HOUR) (“Hour Loop”), a leading online retailer, announces its financial and operational results for the third quarter ended September 30, 2022. Financial Highlights for Third Quarter 2022:Total revenues increased 68.4% and 18.6% to $17.6 million, compared to $10.4 million in the year-ago period and $14.8 million for the second quarter of 2022, respectively. Net income totaled $0.15 million, compared to $0.30 million in the year-ago period and net loss of $0.31 million for the second quarter of 2022. Cash used in operating activities for the nine months ended September...

Continued execution to advance exebacase and CF-370 into new clinical studies YONKERS, N.Y., Nov. 14, 2022 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced financial results and business updates for the third quarter ended September 30, 2022. “I am quite proud of our team at ContraFect, as we worked through significant, unexpected adversity while continuing to successfully execute on our near-term objectives. We submitted a CTA to ANSM, the French regulatory agency, to begin a Phase 1b/2 clinical study of intra-articular exebacase in patients with chronic prosthetic...

MINNEAPOLIS, Nov. 14, 2022 (GLOBE NEWSWIRE) — Northern Technologies International Corporation (NASDAQ: NTIC), a leading developer of corrosion inhibiting products and services, as well as bio-based and biodegradable polymer resin compounds, today reported its financial results for the fourth quarter and fiscal year ended August 31, 2022. Full year fiscal 2022 financial and operating highlights include (with growth rates on a fiscal year-over-year basis):Consolidated net sales increased 31.3% to a record $74,159,000 Consolidated net sales increased 13.6%, excluding sales as a result of the September 2021 acquisition of the remaining 50% ownership in NTIC’s Indian Joint Venture ZERUST® net sales increased 26.1% to $57,459,000 ZERUST® oil and gas net sales increased 21.5% to $4,608,000 NTIC China net sales decreased 9.2% to $15,754,000 Natur-Tec®...

NORCROSS, Ga., Nov. 14, 2022 (GLOBE NEWSWIRE) — Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended September 30, 2022. These results are included in the Company’s Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov. Joel Lewis, Chief Executive Officer and President, stated: “The Company made outstanding progress this quarter. In addition to securing the largest financing in the Company’s history, which extended our cash runway for planned trial expenditures through 2024, we accelerated recruitment on NAVIGATE, our global pivotal NASH cirrhosis trial, and continue to progress towards our goal...